
|Videos|February 7, 2017
A Study of Nivolumab With Nab-Paclitaxel Plus Gemcitabine in Pancreatic Cancer
Author(s)Gabriela Chiorean, MD
Gabriela Chiorean, MD, professor of medicine, discusses an ongoing phase I study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
3
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5




































